Cargando…
Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study
With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potent...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706847/ https://www.ncbi.nlm.nih.gov/pubmed/29212201 http://dx.doi.org/10.18632/oncotarget.21398 |
_version_ | 1783282298700955648 |
---|---|
author | Wang, Yin-Ying Bai, Hong Zhang, Run-Zhi Yan, Hong Ning, Kang Zhao, Xing-Ming |
author_facet | Wang, Yin-Ying Bai, Hong Zhang, Run-Zhi Yan, Hong Ning, Kang Zhao, Xing-Ming |
author_sort | Wang, Yin-Ying |
collection | PubMed |
description | With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potential novel indications of old drugs based on the molecular networks affected by drugs and associated with diseases. Benchmark results on FDA approved drugs have shown the superiority of PINA over traditional computational approaches in identifying new indications of old drugs. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study. The predicted indications, including immune system disorders and tumor, are validated by expert knowledge and evidences from literature, demonstrating the effectiveness of our proposed computational approach. |
format | Online Article Text |
id | pubmed-5706847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57068472017-12-05 Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study Wang, Yin-Ying Bai, Hong Zhang, Run-Zhi Yan, Hong Ning, Kang Zhao, Xing-Ming Oncotarget Research Paper With the ever increasing cost and time required for drug development, new strategies for drug development are highly demanded, whereas repurposing old drugs has attracted much attention in drug discovery. In this paper, we introduce a new network pharmacology approach, namely PINA, to predict potential novel indications of old drugs based on the molecular networks affected by drugs and associated with diseases. Benchmark results on FDA approved drugs have shown the superiority of PINA over traditional computational approaches in identifying new indications of old drugs. We further extend PINA to predict the novel indications of Traditional Chinese Medicines (TCMs) with Liuwei Dihuang Wan (LDW) as a case study. The predicted indications, including immune system disorders and tumor, are validated by expert knowledge and evidences from literature, demonstrating the effectiveness of our proposed computational approach. Impact Journals LLC 2017-09-30 /pmc/articles/PMC5706847/ /pubmed/29212201 http://dx.doi.org/10.18632/oncotarget.21398 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Wang, Yin-Ying Bai, Hong Zhang, Run-Zhi Yan, Hong Ning, Kang Zhao, Xing-Ming Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study |
title | Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study |
title_full | Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study |
title_fullStr | Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study |
title_full_unstemmed | Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study |
title_short | Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study |
title_sort | predicting new indications of compounds with a network pharmacology approach: liuwei dihuang wan as a case study |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706847/ https://www.ncbi.nlm.nih.gov/pubmed/29212201 http://dx.doi.org/10.18632/oncotarget.21398 |
work_keys_str_mv | AT wangyinying predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy AT baihong predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy AT zhangrunzhi predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy AT yanhong predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy AT ningkang predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy AT zhaoxingming predictingnewindicationsofcompoundswithanetworkpharmacologyapproachliuweidihuangwanasacasestudy |